Tailored chemo dosing aims to boost stem cell transplant success in myeloma

NCT ID NCT04483206

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 1 trial is testing a new way to dose the chemotherapy drug melphalan for people with multiple myeloma who are getting a stem cell transplant. Instead of a standard dose, the amount is personalized based on each patient's blood levels after a test dose. The goal is to find the best dose that kills cancer cells while limiting side effects like mouth sores and heart rhythm problems. The study involves 90 participants and will also check if the treatment leads to deeper cancer remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Melphalan (chemotherapy drug)
What this could lead to: If successful, this could lead to more precise melphalan dosing for multiple myeloma patients, potentially improving treatment effectiveness and reducing severe side effects like mouth sores.
What could go wrong: This is an early phase 1 trial with only 90 participants, so results may not apply broadly. The personalized dosing approach is experimental and may not improve outcomes or reduce toxicity as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTRAOSSEOUS PLASMACYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

extramedullary plasmacytoma heavy chain disease non-amyloid monoclonal immunoglobulin deposition disease plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

University Illinois Chicago
NOT_YET_RECRUITING

Chicago, Illinois, 60607, United States
Winship Cancer Institute of Emory University
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.